FORBES-TATE

FORBES-TATE filed a Q1 report for AMGEN USA, INC. on April 17, 2026, reporting $80,000 in lobbying income.

Lobbying for AMGEN USA, INC. · Biotech company that discovers, develops, manufactures and delivers human theraputics

All filings by FORBES-TATE · Everything AMGEN USA, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 17, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medical/Disease Research/Clinical Labs

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Budget/Appropriations

Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Taxation/Internal Revenue Code

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.